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Comparison of immune and adverse effects  
induced by AdjuVac and Freund's complete 
adjuvant i n  New Zealand white rabbits 
(Orycto lagus cun icul us) 
Jenny G. Powers, DvM>~, Paul B. Nnsh, phD1, Jaclc C. Rhyan, DVM, MS1, Christi A. Yoder, PhD1 & 
LowellA. Millei; phD1 
Though Freund's complete adjuvant effectively increases immune response t o  vaccines 
in various species, its potentially severe inflammatory effects have led many animal 
researchers t o  seek alternative immunological adjuvants. In a study of New Zealand white 
rabbits, the authors compared the  immune and adverse effects of Freund's complete 
adjuvant with the effects of two formulations of AdjuVac, an immunological adjuvant 
previously developed by their group. ALL three adjuvants improved humoral immune 
response but also caused inflammation. Inflammatory reactions caused by AdjuVac, 
however, tended to  be Less severe than those caused by Freund's complete adjuvant. 
Of the immunological adjuvants available today, Freund's 
complete adjuvant (FCA) is one of the most effective, yet 
controversial. FCA contains mineral oil (-85%), a man- 
nide monooleate emulsifier (often Aracel A) (-15%) 
and lcilled inycobacteria (typically Mycobacterium tuber- 
culosis or M, butyricunz; -0.1%). This adjuvant is com- 
monly added to weak immunogens to increase immune 
response in vaccinated animals. The initial vaccination 
is routinely followed several weeks later by a booster 
vaccination formulated with Freund's incomplete adju- 
vant (FIA), which is similar to FCA but does not include 
mycobacteria. This vaccination strategy effectively stim~l- 
lates both cell-mediated and humoral immune respons- 
es to a wide variety of antigens'y2. It has been used for 
decades in laboratory and research settings to stimulate 
hyperimmune seruin production as well as protective 
immunity in a broad range of species. 
Along with its benefits, FCA also has distinct disad- 
vantages. Depending on the target species, vaccine dose 
and route of administration, FCA can cause severe local 
and systeinic acute and chronic inflamrnatioi~~-~. The
inflaininatory lesions associated with FCA have been 
attributed to formation of an antigen/adjuvant depot, 
which promotes antigen transport to immune effector 
cells and interactions with antigen-presenting cells8. 
This inflammatory response generates both beneficial 
and detrimental effects. Inflammatory mediators, such 
as leukocytes and cytokines, incite B and T lymphocyte 
activation and differentiation. This triggers specific 
antibody production and activates effector T cells and 
antigen-presenting cellsg. These same processes can also 
induce swelling, erythema and pain, both locally and sys- 
temically. FCKs adverse side effects render it inappropri- 
ate for use in humans or in clinical veterinary settings. 
Concerns about animal welfare have driven researchers 
to look for alternative adjuvants5. 
Numerous studies have compared Freund's adjuvant 
coinbination with alternative adjuvant forinulati~ns'~-'~. 
The results reflect much discrepancy in efficacy and 
secondary side effectsl9. Therefose, the need remains 
for a versatile and effective adjuvant alternative to FCA 
that capitalizes on its benefits while minimizing its 
negative effects. 
AdjuVac, an experimental adjuvant developed and 
previously d e s ~ r i b e d ~ O - ~ ~  by inembers of our group, 
contains small ainounts of Mycobacteriui7z aviunz 
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subspecies aviurn (5200 glml) emulsified in either 
mineral oil or squalene, a biodegradable oil. AdjuVac 
contains microgram quantities of mycobacteria rather 
than the milligram amounts found in FCA and con- 
tains an alternate species of mycobacterium that may 
have different immune stimulatory effects. In addition, 
certain formulations of AdjuVac contain a biodegrad- 
able oil, which may alter depot characteristics. AdjuVac 
has been investigated in domestic cats (Felis c a t z ~ s ) ~ ~ ,  
horses (Eqt~us ~aballus)~', feral swine (Sus s c ~ o f a ) ~ ~  and 
bison (Bison bisot~)~~,  as well as other domestic andlabo- 
ratory animals (L. A. Miller, unpublished observations). 
AdjuVac is primarily intended for use in combination 
with immunocontraceptive vaccines in domestic and 
wild animals. The purpose of this study was to compare 
physiological, histological and pathological changes in 
New Zealand white rabbits (Oryctolagus ctl~zictilus) vac- 
cinated intramuscularly (i.m.) with FCA or with one of 
two formulations of AdjuVac. We investigated biological 
effects that can be attributed primarily to the immune 
system. The antigen we used was a small, nonimmu- 
nogenic self-peptide, gonadotropin releasing hormone 
(GnRH), coupled to a large, highly immunogenic carrier 
protein, keyhole limpet hemocyanin (IUH). 
METHODS 
Rabbits 
We used female New Zealand white rabbits weighing 
2.1-2.7 kg each. We caged each rabbit separately at a 
temperature of 16-20°C with 12-h light:12-h dark 
cycles. We fed rabbits Purina lab diet #5326, a cornmer- 
cial, alfalfa-based, high-fiber pelleted food. Water was 
available ad libitum. 
We divided the 26 rabbits into six treatment groups 
(n  = 4) and one control group (n = 2). Two treatment 
groups were given each of the three types of adjuvant 
used in this study: FCA, AdjuVac formulated with non- 
biodegradable mineral oil (AVM), and AdjuVac formu- 
lated with the biodegradable oil squalene (AVS). One 
of the two groups receiving each adjuvant was given an 
initial vaccination only (100 pg of GnRHIIW), and 
the other group was given an initial vaccination of 50 
pg of GnRHIKLH plus a booster vaccination of 50 pg 
of GnRHIKLH 4 weeks later. All initial vaccinations in 
treatment groups included mycobacteria-containing 
adjuvants. Booster vaccinations were formulated with 
AdjuVac incomplete (without mycobacteria; 2 of 4 rab- 
bits), AdjuVac complete (with mycobacteria; 2 of 4 rab- 
bits) or FM (4 of 4 rabbits). We vaccinated the control 
group with GnRHIKLH in saline without adjuvant. One 
rabbit in the group that was to receive FCA initial vacci- 
nation only died before the beginning of the study, leav- 
ing that group with only three rabbits. 
TO approximate vaccination procedures lilcely to 
be used in a clinical or field setting in various spe- 
cies, we injected rabbits i.m. with 0.5 ml in the 
semimembranosus/semitendinosus musculature. We 
shaved the injection sites using a #40 blade one weelc 
before injection. The initial injections were made in the 
left hind leg, and booster vaccinatioils were made in the 
right hind leg. 
Vaccine preparation 
The GnRH/IZLH/AdjuVac vaccine formulation used 
in these experiments has been previously published20. 
The 10-amino acid GnRH peptide was synthesized at 
Macromolecular Resources, Colorado State University 
(Fort Collins, CO). We increased the antigenicity of the 
hapten by combining multiple copies of the peptide with 
the large immunostimulatory carrier molecule ICLH 
(Pierce Endogen, Rocldord, IL) via maleirnide activated 
coupling24. We combinedthe aqueous GnRHIIZLH con- 
jugate in a 111 ratio (vlv) with the oil-basedadjuvants to 
create water-in-oil emulsions. We prepared the emulsion 
by repeatedly passing the material through a 22-gauge 
needle into an empty syringe until it was stiff. We evalu- 
ated emulsions by checking their dispersion across a 
water surface. 
We prepared AdjuVac adjuvants by modifying the 
commercially available veterinary vaccine Mycopar 
(Fort Dodge Animal Health, Fort Dodge, IA). Using 
either non-biodegradable mineral oil or the biode- 
gradable oil squalene, we diluted small volumes of 
Mycopar until the bacterial fraction was approxi- 
mately equivalent to 200 pglml or less. We prepared a 
similar water-in-oil emulsion vaccine using FCA (85% 
Drake01 5 NF, 15% Aracel A, 0.1% M, butyricum dry 
cells; Calbiochern-Novabiochem Corporation, San 
Diego, CA) or FIA combined with the GnRHIKLH 
aqueous solution. 
Clinical and pathological measurements 
We measured each rabbit's body weight at the start of 
the study and before euthanasia. We observed rabbits 
on a daily basis for clinical signs of pain or systemic ill- 
ness including lack of appetite, lameness, withdrawal or 
vocalization when the injection site was palpated, and 
swelling or erythema at the injection site. With minimal 
animal handling, we recorded rectal temperature before 
treatment and at the start of each sampling session. We 
drew pretreatment blood from a peripheral ear vein for 
evaluation of creatine phosphokinase (CPK) concentra- 
tions and for complete blood counts (CBCs). We drew 
additional venous blood samples for CPK evaluation 
24 h and 72 h after administration of the primary injec- 
tion. We determined serum CPK concentrations using 
CPIC procedure #520 from Sigma Diagnostics (Sigma- 
Aldrich, St. Louis, MO). 
We submitted whole blood collected before treat- 
ment and 72 h after initial injection to Colorado State 
University's Veterinary Diagnostic Laboratory for CBC 
analysis. CBC parameters included: total nucleated cell 
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count, differential, red blood cell count, platelets (all 
cell counts were expressed as cellslpl), plasma protein 
(gldl), hemoglobin concentration (gldl), pack cell vol- 
ume (Yo), mean corpuscular volume (fl), mean corpus- 
cular hemoglobin concentration (gldl) and fibrinogen 
concentration (mgldl). 
Because we collected samples for CPIC evaluation and 
for CBCs before administering booster vaccinations, we 
did not distinguish between single-injection and dual- 
injection groups when analyzing these data. 
We anesthetized each rabbit 12 weeks after initial 
vaccination and collected blood via intracardiac punc- 
ture. We then euthanized rabbits with pentobarbital (390 
mglml) and phenytoin sodium (50 mglml) (Euthasol, 
Delmarva Laboratories, Inc., Midlothian, VA). We car- 
ried out a complete necropsy on each rabbit. We grossly 
examined injection site lesions, measured their volume 
by taking three-dimensional measurements and cal- 
culating cubic volume for the approximate shape, and 
then incised and described them. We placed sections of 
injection site lesions, lung, heart, liver, kidney, spleen, 
duodenum, ovary, uterus, and popliteal and internal 
iliac lymph nodes in 10% neutral buffered formalin and 
processed the samples for histopathological evaluation. 
Injection site lesions were blindly scored on a semi-quan- 
titative scale, using methods similar to those previously 
described17. We evaluated the following characteristics: 
vacuoles, macrophages, giant cells, mature neutrophils, 
lymphocyteslplasma cells and relative necrosis or min- 
eralization. We rated the degree of each characteristic as 
marked (3), moderate (2),mild (1) or absent (0). 
Antibody assay 
We collected blood 2,4, 8 and 12 weeks after initial 
immunization and 2, 4 and 8 weeks after booster 
immunization in dual-injection groups for mea- 
surement of GnRH antibody titers. We determined 
antibody titers using a noncompetitive indirect 
enzyme-linked immunosorbent assay. We conju- 
gated bovine serum albumin-with GnRH and used 
it to coat Immulon 2 HB, 96-well microtiter plates 
(Thermo Electron Corporation, Waltham, MA) using 
a bicarbonate buffer. After incubation, we rinsed 
plates and blocked them with 1:20 Sea Block (Pierce 
Biotechnology, Inc., Roclcford, IL) phosphate-buffered 
saline (PBS) solution. We washed plates with PBS after 
incubating them overnight at 4 OC. We added 100 p1 
of a 1:4,000 dilution of test sera to the first well of 
each row. We serially diluted the sera 1:2 with PBS up 
to 1:512,000. After 2 11 of incubation at room tem- 
perature, we washed the plates and added 100 p1 of 
a 1:3,000 goat antibody to rabbit Iminunoglobulin G, 
conjugated to horseradish peroxidase (Sigma-Aldrich). 
Color was developed by 3,3',5,5' tetrametl~ylbenzidine 
(Sigma-Aldrich). We measured the optical densities 
of individual wells via absorbance using a Dynatech 
MR 5000 microplate reader at a wavelength of 410 nm 
(Dynatech Laboratories, Alexandria, VA). Antibody 
titers were determined when optical density values 
dropped more than 50% between serial dilutions. 
Statistical evaluation 
We analyzed lesion data using analysis of variance 
(PROC GLM). We analyzed all other data as a mixed- 
effects model (PROC MIXED) using SAS version 9.1 
(SAS Institute, 2003), defining significance as P 2 0.05. 
We investigated the effects of treatment, time and the 
interaction of the two factors. 
RESULTS 
Clinical observations 
We intensively monitored rabbits throughout the 
study, and none demonstrated clinical signs of pain 
or lameness. On several occasions rabbits from vari- 
ous treatment groups exhibited small hard nodular 
swellings at the injection sites. These swellings did 
not show external evidence of abscessation or drain- 
ing. There were no significant differences between 
treatment groups in rabbits' overall mean live weights 
(P = 0.6925) or weight gains (P  = 0.6438). Mean 
weights (+ SD) for all rabbits at the start and end of the 
studywere 3.18 + 0.18 kg and 3.83 t- 0.23 kg, respec- 
tively. There were no significant differences between 
treatment groups in mean rectal body temperature 
at any of the sampling points (P  = 0.9775; data not 
shown). In 8 of 189 measurements, rabbits had clini- 
cally elevated rectal temperatures of 39.5 OC or above 
(5 in rabbits treated with AVS, 1 with AVM and 2 
with FCA). 
Creatine phosphokinase 
Serum CPIC concentrations did not differ among 
groups (P = 0.3657) at any time point but did dif- 
fer within each group over time ( P  = 0.0088). In 
all treatment and control groups, serum CPK con- 
centrations increased during the first 24 h after ini- 
tial injection and then decreased between 24 h and 
72 h (Fig. 1). In rabbits treated with AVS and AVM, 
the increase in mean serum CPK concentration dur- 
ing the first 24 11 was moderate, with a drop back to 
baseline between 24 h and 72 11. CPIC concentration 
in control rabbits increased similarly during the first 
24 h. By 72 11 after injection, however, the control rab- 
bits had lower CPIC concentrations than rabbits in 
any of the treatment groups. In rabbits treated with 
FCA, the increase and subsequent decrease in CPIC 
concentration was almost twice as large. Before treat- 
ment, mean CPIC concentratio~ls were significantly 
higher in rabbits treated with FCA than in rabbits in 
the other treatment and control groups (P=0.0385); 
this difference was probably attributable to abnor- 
mally high CPIC concentrations in two of the rabbits 
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Control AVM AVS FCA 
Treatment 
FIGURE 1 ( Serum CPK concentrations (IU/L) before treatment 
and  24 h and 72 h after treatment with different adjuvants. 
Bars indicate standard error. 
in the FCA group. Mean CPI< concentrations before 
treatment for the AVM, AVS and control groups were 
clinically normal (< 400 IU/L)25. 
Compiete blood counts 
We observed few changes over time in CBC parameters. 
Fibrinogen concentration was the only parameter that 
changed consistently between pretreatment and 72 h after 
treatment. Differences in mean fibrinogen concentrations 
between treatment groups only approached significance 
(P = 0.0977; Fig.2). Within each treatment group, there 
was a significant increase in the mean fibrinogen concen- 
trations between pretreatment and 72 h after injection 
(P = 0.0022). Before treatment, fibrinogen concentra- 
tions in all rabbits were within the normal reference range 
(200-400 m g l ~ l l ) ~ ~ .  Rabbits treated with FCA had alarger 
increase in fibrinogen than did rabbits treated with AVM 
(P= 0.0104) but not those treatedwith AVS (P= 0.5433). 
In four rabbits, fibrinogen concentrations exceeded the 
reference range at this time point (500-700 mgldl). Two 
of these four rabbits were treated with AVS, and the other 
two were treated with FCA. 
Antibody production 
We distinguished between initial injections and booster 
injections when evaluating antibody titers. Before vacci- 
nation, no rabbits had measurable GnRH antibody titers. 
After treatment, regardless of adjuvant type, all rabbits 
treated with adjuvants developed high antibody titers (P 
= 0.9612).Neither ofthe control rabbits developed GnRH 
antibody titers. Within 4 weeks of initial vaccination, 2 1 
of the 23 rabbits treated with adjuvants developed GnRH 
antibody titers that were detectable at a serum dilution 
of 1:512,000. Nearly all rabbits maintained this titer until 
necropsy, which was carried out 12 weelcs after the initial 
vaccination. Although the differences were not statisti- 
cally significant, absorbance at a dil~~tion f 1:512,000 was 
initially higher in AVM-treated rabbits (4 weelts after vac- 
cination); however, rabbits treated with single-injection 
FCA had higher absorbance 12 weelts after vaccination 
(Fig. 3). A booster injection at 4 weelts, intended to aug- 
ment antibody responses, did not increase absorbance at 
a dilution of 1:512,000 above values observed in single- 
injection groups. 
Lesions 
We distinguished between initial injections and boost- 
er injections when examining lesion data. Primary 
lesions (left hind leg) differed in size among groups 
(P = 0.0282), whereas differences between secondary 
lesions (right hind leg) only approached statistical sig- 
nificance (P = 0.0683).At necropsy, all adjuvant-treated 
rabbits had lesions at the initial injection site in the left 
rear leg semirnembranosus/semitendinosus musculature. 
Neither control rabbit had any grossly visible injection 
site abnormalities. Affected areas of muscle were typically 
£irm and white or yellow in appearance. Often there were 
discrete nodules within the affected areas. Lesions tended 
to be locally extensive, often dissecting along tissue planes 
and bound by muscle fascia. Two rabbits, one treated 
with AVM and one with FCA, had hard nodules in mus- 
culature distant fiom the injection site. In addition, these 
two rabbits both had popliteal lymph nodes that were 
larger than the contralateral lymph nodes. On average, 
rabbits treated with FCA had the largest lesions (mean 
+_ s.d. = 18.1 + 10.9 cm3). In rabbits treated with both 
primary and booster vaccinations, the second injection 
site lesion tended to be smaller than the primary lesion 
(Table 1). Lesions associated with booster vaccinations in 
the AVS treatment group were smaller than those in the 
AVM treatment group, but not those in the FCA treat- 
ment group. 
I3 Pretreatment I.72hI 
Control AVM AVS FC A 
Treatment 
FIGURE 2 1 Serum fibrinogen concentrations (mg/dl) before 
treatment and  72 h after treatment with different adjuvants. 
Bars indicate standard error. 
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li AVM single El AVM dual 
El AVS single AVS dual 
O FCA single FA dual 
Weeks after immunization 
FIGURE 3 1 Optical density (410 n m )  of G n R H  antibodies over 
time for the six treatment protocols tested, in 1:512,000 serum 
dilution after detection with enzyme-linked immunosorbent 
assay. Bars indicate standard error. The number of vaccinations 
each group received is indicated (single or dual). FA, Freund's 
adjuvant combination. 
At necropsy, all injection site lesions were granuloma- 
tous (Fig. 4). Lesions tended to be partially circumscribed 
with focal inflammatory cell idltrates extending between 
surrounding muscle bundles and myofibers. Often, focal 
degeneration was identified in surrounding myofibers. 
Cellular infiltrates consisted of large sheets of mixed 
irdarnrnatory cells including epithelioid macrophages, 
mature neutrophils, lymphocytes, plasma cells and giant 
cells surrounding small to large vacuoles. The vacuoles 
were considered to be oil droplets. In severallesions, vacu- 
oles were surrounded by heterophils and multinucleated 
giant cells. The vacuoles were occasionally accompanied 
by coagulative necrosis and focal mineralization. 
There were no differences between treatment groups 
in the relative number of vacuoles (P = 0.2164), mac- 
rophages (no P value because all rabbits had the 
same score), giant cells (P  = O.O9SO), neutrophils 
(P = 0.1979) or lymphocytes (P = 0.2455). Necrosis 
and mineralization scores clid not differ between treat- 
ment groups (P = 0.4922 and P = 0.6256, respectively; 
Table 2). 
Additional histopathological observations 
In all treated rabbits, reproductive tracts, including 
uterus and ovaries, were small and immature on gross 
examination. Reproductive tracts in control rabbits 
were clinically normal. Examination of a midline cut 
surface of one or both ovaries rarely revealed follicles. 
Those follicles that were present appeared smaller than 
those seen in control rabbits. Three treated rabbits had 
enlarged popliteal lymph nodes. There was no correla- 
tion between lymph node enlargement and treatment 
group (P = 0.2663). We did not observe gross abnormal- 
ities in lung, heart, liver, kidney, spleen or duodenum 
tissues in any experimental rabbits. 
DISCUSSION 
This study compared the biological effects of FCA, 
AVM and AVS when combined with a common anti- 
gen and injected into domestic laboratory rabbits. Our 
results showed that primary deep i.m. injections with 
water-in-oil emulsions containing killed mycobac- 
teria are effective in inducing high levels'of antibody 
production but cause granuloma formation and acute 
and chronic inflammation. This finding is consistent 
with those of numerous studies investigating the use 
of Freund's This study is unique 
in that it evaluated potentially subtle differences in the 
severity of the immune-mediated effects generated by 
the three adjuvants tested. 
None of the treatment groups in this study exhibited 
the more severe systemic and local inflammatory reac- 
tions reported to be associated with FCA, such as lack 
of appetite, lameness, ulceration, necrotizing derma- 
titis, muscle atrophy, fistulous tracts, hypersensitivity 
pnuemonitis and embolic p n e ~ m o n i a ~ l ' ~ .  There were, 
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FIGURE 4 1 Photomicrograph of injection site lesion produced 
by vaccination with FCA. The lesion is characteristic of those 
produced by aLl treatments and contains small to large vacuoles 
(V) surrounded by macrophages (M), multinucleated giant cells 
(arrows) and focal accumulations of Lymphocytes and plasma 
cells (LP). Bar represents 60 wm. 
however, many indications of inflammation in all treat- 
ment groups. All rabbits, including the control group 
(vaccinated with salinelantigen), had increased serum 
CPK concentrations after vaccination. CPK is primarily 
a cytosolic enzyme of myocytes, released when the cell 
membrane is damaged and the cell undergoes myone- 
aosis. CPK has a short plasma half-life, and serum levels 
usually return to normal 2-3 d after the cessation of the 
insult or injury2'. CPK is therefore a good indicator of 
acute muscle damage. In this case, the myonecrosis may 
have resulted from tissue trauma from the needle com- 
bined with the physical presence of the vaccine in the 
muscle, in addition to the vaccine's molecular function. 
FCA and other adjuvants have been shown to increase 
CPK concentration in similar s t ~ d i e s ~ ~ y ~ ~ .  In this study, 
although the difference was not statistically significant, 
treatment with FCA was associated with the highest 
mean CPK concentration 24 h after treatment. Given 
the variation observed, our power to detect a difference 
between groups was 21.8% (a = 0.05). Therefore, we may 
not have detected a difference between groups because of 
inadequate sample size, rather than a true lack of diver- 
gence between the treatment groups. 
Two rabbits whose CPIC values were outliers and were 
elevated at all time points increased the mean CPIZ con- 
centration in the FCA treatment group; however, tile rela- 
tive change in their CPIC concentrations over time was 
similar to that of other FCA-treated rabbits. Although 
their veterinary records did not indicate that the rabbits 
had experienced increased handling stress, stress could 
have contributed the elevation in their initial serum CPIC 
concentrations. CPIC concentrations of most rabbits 
exceeded the normal range (3350-400 IU/L) 24 h after 
vaccination, although none of the values were clinically 
extreme. We conclude that myonecrosis occurred in asso- 
ciation with immunization, that it may have been more 
severe in FCA-treated rabbits and that it was diminished 
within 72 h after immunization. 
Like CPK, plasma concentrations of fibrinogen can 
act as a measure of inflammation. Fibrinogen is an acute 
phase-reactant protein produced by the liver, which 
serves as a substrate for thrombin in the formation of 
fibrin during homeostasis. Increased fibrinogen con- 
centration is a good indicator of active inflammation 
and is useful in assessing an inflammatory response29. 
In FCA-treated rabbits, fibrinogen concentrations were 
consistently higher 72 h after vaccination than before 
treatment (average increase was 200 mg/dl). In two of 
seven FCA-treated rabbits, the increased fibrinogen 
concentrations exceeded the normal range in rabbits 
(200-400 mg/dl)26. Though mean fibrinogen concen- 
trations also increased over time in rabbits treated with 
AVM and AVS, the increase was neither as consistent nor 
as high as that observed in the FCA treatment groups. 
Our power to detect differences in fibrinogen concen- 
trations between groups was 14.9%. Small sample size 
and relatively large variation in both fibrinogen and CPK 
concentrations limited our ability to detect statistically 
significant increases in these indicators of inflammation. 
However, both trends suggest that FCA-treated rabbits 
had greater acute inflammation. 
AVM AVS FA 
Vacuole 2.43 + 0.93 2.25 + 0.43 2.71 + 0.45 
Macrophage 3.00 + 0.00 3.00 + 0.00 3.00 1 0.00 
Giant Celk 1.00 + O.OOa 1.63 + 0 .70~  1.29 + 0.45 
Neutrop hils 1.29 * 0.45 1.50 + 0.50 1.86 * 0.64 
Lymphocytes 1.43 + 0.49 1.75 % 0.66 2.00 % 0.53 
Necrosis 0.29 * 0.45 0.50 * 0.71 0.14 -1 0.35 
Mineralization 0.43 + 0.49 0.38 + 0.70 0.14 + 0.35 
Values shown are the mean * s.d. of  the degree to which each histological feature was present, using the following scale: 3, marked; 2, moderate; 1, mild: 0, absent. Means 
within rows with different superscripts are significantly different from one another (P c 0.05). Values without superscripts are not significantly different from any other 
values in  the row. 
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Gross and histopathological examination of primary 
injection site lesions showed moderate to severe focal 
chronic granulomatous inflammation in all rabbits 
treated with adjwants. Granulomatous inflammation is 
classically characterized by well-circumscribed areas of 
large numbers of modified tissue macrophage; (epitheli- 
oid cells or multinucleate giant cells), polymorphonuclear 
leulrocytes and lymphocytes. Granulomas generally form 
in response to a chronic inflamlnatory stimulus such as 
an indigestible foreign protein or a type IV hypersensi- 
tivity reaction and may remain in tissue for the dura- 
tion of the stimulus. In this study, though the differences 
were not statistically significant, lesion size tended to 
be larger in volume with higher numbers of oil-droplet 
vacuoles, mature neutrophils and lymphocytes in FCA- 
treated rabbits than in rabbits treated with AVM or AVS. 
All groups had equally extensive lesion infiltration with 
macrophages. Lesions associated with booster vaccina- 
tions (right leg) were smaller in rabbits treated with AVS 
than in those treated with AVM. Though this is probably 
an artifact of small sample size (power is 37-49%), it may 
indicate that biodegradable oil incites less chronic inflarn- 
mation during the secondary or anamnestic response 
than non-biodegradable mineral oil. Additional experi- 
ments would be necessary to investigate this hypothesis. 
Antibody production in all adjuvant-treated rabbits was 
high. Over the course of the 12-week study, we observed 
no difference in the effects of the various adjuvant types 
and immunization protocols on antibody production 
or persistence. Nearly all treated rabbits had detectable 
GnRH antibody titers at a dilution of 1:512,000 by 4 weeks 
after the initialvaccination. In previous experiments with 
similar immunization protocols in other species, antibody 
titers at dilutions greater than 1:400,000 (domestic cats)20 
and 1:100,000 (bison)23 were shown. Limitations of the 
enzyme-linked immunosorbent assay did not allow us to 
quantitatively measure antibody production beyond this 
dilution; we were therefore unable to identify end-point 
titer differences between treatment groups. Analysis of the 
optical density at this dilution did not show any differ- 
ences between treatment groups. This may be due to our 
low power to detect differences (38.7%) rather than a true 
lack of treatment effect. Though the difference was not 
statistically significant, rabbits treated with FCA contin- 
ued to show increased absorbance at the 1:512,000 dilu- 
tion 12 weelts after treatment, whereas absorbance levels 
in all other treatment groups dropped between 8 and 12 
weelts. Therefore, it is possible that FCA incites a more 
potent humoral immune reaction than AVM or AVS. 
Larger sample sizes, a more complete assay and longer 
experimental duration would be necessary to determine 
whether different treatments have different effects on anti- 
body productioll and persistence. Our study does show 
that AVM, AVS and FCA effectively stimulate humoral 
immune responses in rabbits with a single immunization 
or in conjunction with a booster vaccination. 
Elevated GnRH antibody titers correlated well with 
relative immaturity of the reproductive tract. On gross 
examination, all rabbits vaccinated with a water-in-oil- 
based adjuvant had small, underdeveloped ovaries with 
few or no visible follicles. Control rabbits vaccinated 
with GnRH-ICLH in saline had larger ovaries and uteri 
and follicles of various sizes. Microscopically, ovaries 
from treated rabbits contained primordial follicles and 
small numbers of preantral follicles but no antral or pre- 
ovulatory follicles. Whereas ovaries from control rabbits 
showed normal postpubertal follicular development, 
ovaries from treated rabbits were characteristic of prepu- 
bertal development. 
No single physiological parameter provides a complete 
picture of the safety and efficacy of a vaccine formulation. 
Considered together, however, the inflammatory indica- 
tors we investigated can point to certain trends. Rabbits 
treatedwith FCAshowed more signs of acute and chronic 
inflammation, resulting in larger primary lesions, than 
rabbits treated with AVM or AVS. Secondary lesions 
resulting from FIA booster injections were not larger 
than secondary lesions resulting from AdjuVac. The two 
AdjuVac formulations also showed evidence of inciting 
inflammation, in the form of injection site granulomas. 
Lesions resulting from the initial vaccination and from 
the booster vaccination were smaller in the AVS group 
than in the AVM group. 
This research reconfirms that water-in-oil-based 
adjuvants with mycobacterial fractions can initiate 
high antibody production, while inducing physiologi- 
cal changes consistent with acute and chronic inflam- 
mation. The amount and type of mycobacteria used 
may affect the severity of inflammation. The type of oil 
we used in the AdjuVac emulsion (non-biodegradable 
mineral oil or squalene) did not seem to affect indica- 
tors of inflammation or antibody production during 
this 12-week study, but a study with more robust sam- 
ple sizes is needed to confirm or refute this hypothesis. 
AdjuVac effectively induces humoral immunity as well 
as moderate localized inflammation when paired with 
the GnRH-ICLH antigen. 
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